SYNGENE - Syngene International Limited Share Price

Healthcare Services

₹620.60-25.95(-4.01%)

Market Closed as of Nov 6, 2025, 15:30 IST

Select time range

Valuation
Market Cap	26.04 kCr
Price/Earnings (Trailing)	55.42
Price/Sales (Trailing)	6.82
EV/EBITDA	23.41
Price/Free Cashflow	63.17
MarketCap/EBT	42.84
Enterprise Value	25.84 kCr

Fundamentals
Revenue (TTM)	3.82 kCr
Rev. Growth (Yr)	2%
Earnings (TTM)	468.2 Cr
Earnings Growth (Yr)	-36.8%

Profitability
Operating Margin	17%
EBT Margin	17%
Return on Equity	10.73%
Return on Assets	7.46%
Free Cashflow Yield	1.58%

Price to Sales Ratio

Latest reported: 7

Revenue (Last 12 mths)

Latest reported: 4 kCr

Net Income (Last 12 mths)

Latest reported: 468 Cr

Growth & Returns
Price Change 1W	-1.7%
Price Change 1M	1.7%
Price Change 6M	5.8%
Price Change 1Y	-25.3%
3Y Cumulative Return	1.3%
5Y Cumulative Return	3.3%
7Y Cumulative Return	12%
10Y Cumulative Return	13.8%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-744.7 Cr
Cash Flow from Operations (TTM)	1.17 kCr
Cash Flow from Financing (TTM)	-141.8 Cr
Cash & Equivalents	327.2 Cr
Free Cash Flow (TTM)	407.3 Cr
Free Cash Flow/Share (TTM)	10.11

Balance Sheet
Total Assets	6.54 kCr
Total Liabilities	1.81 kCr
Shareholder Equity	4.73 kCr
Current Assets	2.05 kCr
Current Liabilities	1.19 kCr
Net PPE	2.57 kCr
Inventory	189.3 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.02
Debt/Equity	0.03
Interest Coverage	11.45
Interest/Cashflow Ops	23.03

Dividend & Shareholder Returns
Dividend/Share (TTM)	1.25
Dividend Yield	0.19%
Shares Dilution (1Y)	0.10%
Shares Dilution (3Y)	0.40%

Pros

Profitability: Recent profitability of 13% is a good sign.

Size: Market Cap wise it is among the top 20% companies of india.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Smart Money: Smart money has been increasing their position in the stock.

Technicals: Bullish SharesGuru indicator.

Balance Sheet: Strong Balance Sheet.

Cons

Past Returns: Underperforming stock! In past three years, the stock has provided 1.3% return compared to 13.5% by NIFTY 50.

Momentum: Stock has a weak negative price momentum.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	0.19%
Dividend/Share (TTM)	1.25
Shares Dilution (1Y)	0.10%
Earnings/Share (TTM)	11.66

Financial Health
Current Ratio	1.64
Debt/Equity	0.03

Technical Indicators
RSI (14d)	62.92
RSI (5d)	31.9
RSI (21d)	54.14
MACD Signal	Buy
Stochastic Oscillator Signal	Hold
Grufity Signal	Buy
RSI Signal	Hold
RSI5 Signal	Hold
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Latest News and Updates from Syngene International

Updated May 5, 2025

The Bad News

Mint

Syngene's stock has declined by 26.85% this year, reflecting significant downward pressure.

Mint

The stock price dropped by 1.03% today, with a recent trading range showing volatility.

Mint

Foreign Institutional Investor holdings have decreased to 19.47%, indicating reduced confidence among larger investors.

The Good News

Mint

Syngene International reported a net profit of 183.30 Crores in the last quarter, indicating operational strength.

Mint

Mutual Fund holdings in Syngene have increased to 17.86%, suggesting some level of investor confidence.

Mint

Among analysts, 2 recommend a strong buy for Syngene, indicating that some experts see potential upside.

Updates from Syngene International

Investor Presentation • 06 Nov 2025

Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Press Release / Media Release • 05 Nov 2025

Press Release dated November 05, 2025.

General • 04 Nov 2025

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Change in Management • 28 Oct 2025

Appointment of Mr. Surender Sharma as General Counsel and a member of the Executive Committee (Senior Management Personnel) of the Company w.e.f. October 28, 2025.

Clarification • 23 Oct 2025

The Exchange has sought clarification from Syngene International Ltd on October 23, 2025, with reference to news appeared in www.thehindubusinessline.com dated October 23, 2025 quoting ....

General • 18 Oct 2025

Email communication to shareholders under 100 Days Campaign - "Saksham Niveshak"

Newspaper Publication • 14 Oct 2025

Newspaper Advertisement - Notice to shareholders 100-day Campaign - Saksham Niveshak

This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.

Summary of Latest Earnings Report from Syngene International

Summary of Syngene International's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated:

Q&A Session

Last updated:

Share Holdings

Understand Syngene International ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
BIOCON LIMITED	52.41%
ICICI PRUDENTIAL ELSS TAX SAVER FUND	4.82%
DSP ARBITRAGE FUND	4.32%
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHA	3.45%
MIRAE ASSET ARBITRAGE FUND	3.06%
GOVERNMENT OF SINGAPORE	2.91%
LICI NEW ENDOWMENT PLUS-GROWTH FUND	1.78%
UTI-FLEXI CAP FUND	1.54%
BIOCON LIMITED EMPLOYEE WELFARE TRUST (MURALI KRISHNAN K N and K NANDA KUMAR)	0.26%
BIOCON RESEARCH LIMITED	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Syngene International Better than it's peers?

Detailed comparison of Syngene International against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.06 LCr	56.98 kCr	+3.80%	-6.40%	38.82	7.13	-	-
DIVISLAB	Divi's Lab	1.81 LCr	10.04 kCr	+16.20%	+15.50%	78.53	18.02	-	-
LAURUSLABS	Laurus Labs	53.07 kCr	6.46 kCr	+13.70%	+101.70%	77.53	8.21	-	-
BIOCON	Biocon	50.94 kCr	15.95 kCr	+8.20%	+22.60%	118.32	3.19	-	-
JUBLPHARMA	JUBILANT PHARMOVA	18.82 kCr	7.66 kCr	+5.50%	-5.70%	39.17	2.46	-	-

Sector Comparison: SYNGENE vs Healthcare Services

Comprehensive comparison against sector averages

Comparative Metrics

SYNGENE metrics compared to Healthcare

Category	SYNGENE	Healthcare
PE	51.16	67.15
PS	6.85	7.11
Growth	6.8 %	7.7 %

Performance Comparison

SYNGENE vs Healthcare (2021 - 2025)

Key Insights

1. SYNGENE is among the Top 10 Healthcare Services companies but not in Top 5.
2. The company holds a market share of 4.5% in Healthcare Services.
3. The company is growing at an average growth rate of other Healthcare Services companies.

Income Statement for Syngene International

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	4.4%	3,642	3,489	3,193	2,604	2,184	2,012
Other Income	-21.1%	72	91	71	53	65	82
Total Income	3.8%	3,714	3,579	3,264	2,657	2,249	2,094
Cost of Materials	5.8%	925	874	902	771	552	519
Employee Expense	10.7%	984	889	842	718	660	580
Finance costs	13%	53	47	45	24	28	35
Depreciation and Amortization	1.6%	433	426	366	310	274	219
Other expenses	2.9%	674	655	557	341	326	294
Total Expenses	4.7%	3,086	2,947	2,670	2,142	1,815	1,648
Profit Before exceptional items and Tax	-0.6%	628	632	594	515	434	446
Exceptional items before tax	356.2%	32	-11.1	0	-30.7	35	71
Total profit before tax	6.3%	660	621	594	484	469	517
Current tax	12.3%	138	123	117	89	74	90
Deferred tax	281.8%	25	-12.2	12	0	-10.2	15
Total tax	48.2%	164	111	129	89	64	105
Total profit (loss) for period	-2.8%	496	510	464	396	405	412
Other comp. income net of taxes	-111.1%	-14.7	143	-97.2	43	191	-191.6
Total Comprehensive Income	-26.2%	482	653	367	439	596	220
Earnings Per Share, Basic	-3.1%	12.35	12.71	11.59	9.94	10.18	10.38
Earnings Per Share, Diluted	-3%	12.34	12.69	11.51	9.82	10.11	10.35

Description	(%) Q/Q	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	4.2%	911	874	1,018	944	891	790
Other Income	-17.6%	15	18	19	18	16	18
Total Income	3.8%	926	892	1,037	962	908	808
Cost of Materials	-5%	228	240	228	242	231	168
Employee Expense	5%	275	262	253	250	252	230
Finance costs	9.1%	13	12	16	12	13	12
Depreciation and Amortization	4.5%	116	111	106	109	111	107
Other expenses	4.8%	198	189	186	173	158	156
Total Expenses	6.3%	841	791	796	781	770	738
Profit Before exceptional items and Tax	-16%	85	101	240	181	137	69
Exceptional items before tax	-	0	0	0	0	0	32
Total profit before tax	-16%	85	101	240	181	137	101
Current tax	-22.7%	18	23	47	45	27	19
Deferred tax	93.5%	0.4	-8.2	10	4.8	3.8	6.4
Total tax	21.4%	18	15	57	50	31	26
Total profit (loss) for period	-23.3%	67	87	183	131	106	76
Other comp. income net of taxes	-799%	-138.8	21	55	-56.9	-40.3	27
Total Comprehensive Income	-167.9%	-71.7	108	239	74	66	103
Earnings Per Share, Basic	-42.2%	1.67	2.16	4.56	3.27	2.64	1.89
Earnings Per Share, Diluted	-41.7%	1.67	2.15	4.56	3.26	2.64	1.88

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	5.3%	3,373	3,203	3,194	2,601	2,179	2,012
Other Income	-20.7%	70	88	71	53	65	82
Total Income	4.7%	3,444	3,291	3,264	2,654	2,244	2,094
Cost of Materials	3.5%	868	839	902	771	552	519
Employee Expense	10.7%	842	761	812	698	642	572
Finance costs	3.4%	31	30	45	24	28	35
Depreciation and Amortization	-0.5%	367	369	359	310	274	219
Other expenses	9.3%	729	667	587	361	341	304
Total Expenses	4.8%	2,854	2,723	2,664	2,142	1,812	1,649
Profit Before exceptional items and Tax	3.9%	590	568	601	512	432	444
Exceptional items before tax	356.2%	32	-11.1	0	-30.7	35	71
Total profit before tax	11.7%	622	557	601	482	467	516
Current tax	20.2%	120	100	116	88	74	89
Deferred tax	430%	34	-9	12	0	-9.9	15
Total tax	70%	154	91	128	88	64	104
Total profit (loss) for period	0.4%	468	466	473	394	404	412
Other comp. income net of taxes	-106.4%	-8.1	143	-97.2	43	191	-191.6
Total Comprehensive Income	-24.6%	460	610	376	437	594	220
Earnings Per Share, Basic	0.2%	11.64	11.62	11.81	9.89	10.15	10.36
Earnings Per Share, Diluted	0.2%	11.63	11.61	11.72	9.77	10.08	10.33

Description	(%) Q/Q	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	3.9%	830	799	948	877	821	726
Other Income	-18.8%	14	17	18	18	16	18
Total Income	3.4%	844	816	967	895	838	744
Cost of Materials	-9.9%	201	223	213	229	216	210
Employee Expense	6.1%	226	213	209	213	224	196
Finance costs	30.6%	7.4	5.9	10	6.7	7	7.4
Depreciation and Amortization	5.3%	100	95	90	92	94	92
Other expenses	-1.8%	214	218	209	189	167	164
Total Expenses	3.8%	760	732	738	725	713	677
Profit Before exceptional items and Tax	0%	84	84	229	170	124	67
Exceptional items before tax	-	0	0	0	0	0	32
Total profit before tax	0%	84	84	229	170	124	99
Current tax	-20%	13	16	41	40	21	17
Deferred tax	160.6%	5	-5.6	13	6.5	6.7	7.7
Total tax	88.9%	18	10	54	47	28	25
Total profit (loss) for period	-11%	66	74	174	123	97	74
Other comp. income net of taxes	-938.9%	-150	19	60	-55	-39.5	27
Total Comprehensive Income	-192.2%	-83.8	93	234	68	57	101
Earnings Per Share, Basic	-22.6%	1.65	1.84	4.34	3.07	2.41	1.84
Earnings Per Share, Diluted	-21.7%	1.65	1.83	4.33	3.06	2.41	1.84

Balance Sheet for Syngene International

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-10.9%	327	367	221	86	168	90
Current investments	-16.3%	511	610	503	513	492	824
Total current financial assets	-16%	1,681	2,002	1,592	1,608	1,962	1,987
Inventories	21.3%	189	156	170	238	320	333
Total current assets	-10.4%	2,050	2,287	1,877	1,959	2,375	2,425
Property, plant and equipment	10.7%	2,572	2,323	2,794	2,378	2,682	2,383
Capital work-in-progress	-21.6%	989	1,261	904	837	236	177
Investment property	3%	35	34	38	41	44	48
Non-current investments	0%	36	36	36	35	48	94
Total non-current financial assets	-14.3%	216	252	232	258	271	329
Total non-current assets	-0.4%	4,492	4,509	4,259	4,193	3,471	3,406
Total assets	-3.7%	6,542	6,796	6,136	6,152	5,846	5,831
Borrowings, non-current	-	0	0	100	100	141	489
Total non-current financial liabilities	4.6%	430	411	528	465	420	725
Provisions, non-current	-102.4%	0	43	47	41	36	44
Total non-current liabilities	-8.6%	615	673	800	750	729	1,025
Borrowings, current	3.4%	124	120	59	42	378	86
Total current financial liabilities	8.6%	648	597	520	413	794	466
Provisions, current	2.9%	73	71	82	73	74	51
Current tax liabilities	48.6%	12	8.4	54	48	20	15
Total current liabilities	-14.6%	1,192	1,396	941	1,144	1,226	1,188
Total liabilities	-12.7%	1,807	2,069	1,740	1,894	1,955	2,213
Equity share capital	0.2%	403	402	402	402	402	401
Total equity	0.2%	4,735	4,727	4,396	4,258	3,891	3,618
Total equity and liabilities	-3.7%	6,542	6,796	6,136	6,152	5,846	5,831

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-14.2%	201	234	179	67	128	72
Current investments	-16.9%	497	598	495	493	488	824
Total current financial assets	-17.7%	1,492	1,812	1,503	1,543	1,852	1,927
Inventories	22.8%	184	150	166	234	315	333
Total current assets	-12.6%	1,777	2,034	1,734	1,852	2,233	2,355
Property, plant and equipment	13.3%	2,260	1,994	2,256	2,066	2,175	2,140
Capital work-in-progress	-37.2%	550	875	809	758	146	126
Investment property	3%	35	34	38	41	45	48
Non-current investments	0%	870	870	436	435	448	116
Total non-current financial assets	-3.5%	1,042	1,080	626	652	666	336
Total non-current assets	-1.1%	4,327	4,373	4,016	3,982	3,279	2,964
Total assets	-4.7%	6,104	6,407	5,750	5,834	5,512	5,848
Borrowings, non-current	-	0	0	101	100	141	489
Total non-current financial liabilities	12.8%	203	180	294	262	218	562
Provisions, non-current	-102.6%	0	40	44	38	34	42
Total non-current liabilities	-11.6%	388	439	563	544	526	860
Borrowings, current	5%	107	102	42	42	378	86
Total current financial liabilities	7.6%	583	542	457	382	733	440
Provisions, current	-3.1%	64	66	76	68	69	48
Current tax liabilities	-100%	1	4	52	46	13	13
Total current liabilities	-17.5%	1,096	1,329	869	1,099	1,152	1,157
Total liabilities	-16.1%	1,484	1,768	1,432	1,642	1,677	2,229
Equity share capital	0.2%	403	402	402	402	402	401
Total equity	-0.4%	4,620	4,639	4,318	4,192	3,835	3,619
Total equity and liabilities	-4.7%	6,104	6,407	5,750	5,834	5,512	5,848

Cash Flow for Syngene International

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	18.2%	53	45	34	18	-	-
Change in inventories	-36%	74	115	-153.4	-119.8	-	-
Depreciation	1.6%	433	426	366	310	-	-
Impairment loss / reversal	-	0	0	0	37	-	-
Unrealised forex losses/gains	78.3%	0	-3.6	24	22	-	-
Dividend income	-	0	0	0	6.3	-	-
Adjustments for interest income	-6.8%	56	60	60	46	-	-
Share-based payments	7300%	37	0.5	24	37	-	-
Net Cashflows from Operations	9.9%	1,283	1,167	960	686	-	-
Income taxes paid (refund)	-8.1%	115	125	137	106	-	-
Net Cashflows From Operating Activities	12.1%	1,168	1,042	824	581	-	-
Cashflows used in obtaining control of subsidiaries	-100.2%	0	553	18	0	-	-
Purchase of property, plant and equipment	54.6%	760	492	507	475	-	-
Purchase of intangible assets	-51.1%	9.8	19	12	0.2	-	-
Proceeds from sales of long-term assets	-104.8%	0	22	0	0	-	-
Interest received	-39.5%	50	82	54	26	-	-
Other inflows (outflows) of cash	-105.6%	-24.9	465	-171	-157.4	-	-
Net Cashflows From Investing Activities	-50.2%	-744.7	-495.6	-656.4	-611.5	-	-
Proceeds from issuing shares	-	0.5	0	0	0	-	-
Proceeds from borrowings	-	17	0	0	0	-	-
Repayments of borrowings	-90.6%	42	436	258	5.8	-	-
Payments of lease liabilities	47.2%	54	37	9.8	8	-	-
Dividends paid	0%	50	50	40	0	-	-
Interest paid	-53.6%	14	29	34	18	-	-
Net Cashflows from Financing Activities	74.1%	-141.8	-551.4	-342.5	-31.3	-	-
Effect of exchange rate on cash eq.	-800%	0.3	1.1	3.1	0.7	-	-
Net change in cash and cash eq.	5933.3%	281	-3.8	-172.3	-61.5	-	-

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	11.1%	31	28	34	18	-	-
Change in inventories	-28%	86	119	-153.4	-119.8	-	-
Depreciation	-0.5%	367	369	359	310	-	-
Impairment loss / reversal	-	0	0	0	37	-	-
Unrealised forex losses/gains	76.7%	0	-3.3	24	22	-	-
Dividend income	-	0	0	0	6.3	-	-
Adjustments for interest income	-	55	0	60	46	-	-
Share-based payments	1805.9%	30	-0.7	21	37	-	-
Net Cashflows from Operations	20.1%	1,215	1,012	972	686	-	-
Income taxes paid (refund)	4.1%	102	98	134	104	-	-
Net Cashflows From Operating Activities	22%	1,114	913	838	582	-	-
Cashflows used in obtaining control of subsidiaries	-100.1%	0	931	18	0	-	-
Purchase of property, plant and equipment	5.1%	369	351	521	475	-	-
Proceeds from sales of intangible assets	-104.8%	0	22	0	0	-	-
Purchase of intangible assets	-49.3%	8.6	16	12	0.2	-	-
Interest received	-38.8%	50	81	54	26	-	-
Other inflows (outflows) of cash	-110.1%	-48.7	495	-166	-157.4	-	-
Net Cashflows From Investing Activities	-111%	-810.4	-383.5	-688.2	-611.5	-	-
Proceeds from issuing shares	-	0.5	0	0	0	-	-
Repayments of borrowings	-90.6%	42	436	258	5.8	-	-
Payments of lease liabilities	-	32	0	7.6	8	-	-
Dividends paid	0%	50	50	40	0	-	-
Interest paid	-29.4%	13	18	34	18	-	-
Net Cashflows from Financing Activities	74.4%	-136.5	-536.3	-340.2	-31.3	-	-
Effect of exchange rate on cash eq.	-900%	0	0.9	3.1	0.7	-	-
Net change in cash and cash eq.	2653.8%	167	-5.5	-186.9	-59.9	-	-

What does Syngene International Limited do?

Healthcare Research, Analytics & Technology•Healthcare•Mid Cap

Syngene International is a Healthcare Research, Analytics & Technology company, traded under the stock ticker SYNGENE and boasting a market capitalization of Rs. 24,834.5 Crores. Established in 1993 and headquartered in Bengaluru, India, it operates as a contract research and manufacturing organization.

The company specializes in a wide array of drug discovery and development services, serving clients in India, the United States, Europe, and globally.

Key Services Offered:

Discovery Chemistry Services: This includes synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry.
Discovery Biology Services: The areas covered here are recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, and various aspects of pharmacology and toxicology.
Development Services: This encompasses chemical, formulation, analytical, and clinical development, alongside commercial manufacturing and sterile fill-finish services.

Further services include lead generation, preclinical development, API and drug product development, clinical trial management, bioanalytical studies, biometrics, and medical writing. The company is equipped to handle a range of therapeutic modalities, including traditional small molecules and biologics.

Syngene serves diverse sectors, including pharmaceuticals, biotechnology, animal health, nutrition, consumer goods, and agrochemicals. Notably, it has collaborated with significant industry names such as Bristol-Myers Squibb, Baxter Inc., and Amgen Inc..

Financially, Syngene reported trailing 12-month revenues of Rs. 3,610.3 Crores and a profit of Rs. 501.5 Crores over the past four quarters. The company has experienced a 41% revenue growth over the past three years and has a dividend yield of 0.3%, distributing Rs. 2.5 in dividends per share in the last year. However, it has diluted its investor holdings by 0.4% during the same period.

In conclusion, Syngene International Limited stands out as a profitable entity in the healthcare research space with a strong emphasis on collaboration and diverse service offerings.

Industry Group:Healthcare Services

Employees:6,510

Website:www.syngeneintl.com

SYNGENE - Syngene International Limited Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

The Bad News

The Good News

Updates from Syngene International

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Syngene International Limited do?